Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + mitoxantrone + vincristine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three antineoplastic agents—methotrexate, mitoxantrone, and vincristine. Each drug has a distinct mechanism of action targeting cancer cell proliferation: - Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking DNA synthesis and cell replication. - Mitoxantrone is an anthracenedione that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. - Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation during mitosis and causing cell cycle arrest at metaphase. The combination has been studied as first-line therapy for advanced breast cancer (MIMO regimen), showing objective response rates around 42% with manageable toxicity profiles. It has also been used in other malignancies in various combinations[2][8].
- Other names
- MIMO
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on methotrexate + mitoxantrone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + mitoxantrone + vincristine.